ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2017
Novel "Add-On" Molecule Based on Evans Blue Confers Superior Pharmacokinetics and Transforms Drugs to Theranostic Agents.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 72 citations in OpenAlex.
- Cancer theranostics.Nature reviews. Cancer · 2026Review
- Linker Chemistry in Radiopharmaceutical Design.Bioconjugate chemistry · 2026Review
- A peptide nucleic acid-based pretargeting approach usingEJNMMI research · 2026Article
- Biodistribution-Driven Discovery Identifies a Glycosidase-Cleavable Linker to Reprogram Radiotheranostics.bioRxiv : the preprint server for biology · 2025Article
- Fibroblast activation protein targeting radiopharmaceuticals: From drug design to clinical translation.Acta pharmaceutica Sinica. B · 2025Review
- Development of Novel Integrin αACS medicinal chemistry letters · 2025Article
- Deciphering the Tumor Uptake of Heterobivalent (SSTJournal of medicinal chemistry · 2025Article
- Tissue-seeking dyes for in vivo applications.Smart molecules : open access · 2024Review
- Development of [European journal of nuclear medicine and molecular imaging · 2024Article
- Effect of Linker Entities on Pharmacokinetics ofACS pharmacology & translational science · 2024Article
- EGFR- and Integrin αInternational journal of molecular sciences · 2024Review
- Optimizing the pharmacokinetics of anEuropean journal of nuclear medicine and molecular imaging · 2024Article
- HSA-nanobinders crafted from bioresponsive prodrugs for combined cancer chemoimmunotherapy-anFrontiers in chemistry · 2024Article
- Development of probes for radiotheranostics with albumin binding moiety to increase the therapeutic effects of astatine-211 (European journal of nuclear medicine and molecular imaging · 2024Article
- Preclinical evaluation of a dual-receptor targeted tracer [European journal of nuclear medicine and molecular imaging · 2023Article
- The preclinical study ofAnnals of nuclear medicine · 2023Article
- [European journal of nuclear medicine and molecular imaging · 2023Article
- Palmitic Acid-Conjugated Radiopharmaceutical for Integrin αPharmaceutics · 2022Article
- Deciphering albumin-directed drug delivery by imaging.Advanced drug delivery reviews · 2022Review
- Structure‒tissue exposure/selectivity relationship (STR) correlates with clinical efficacy/safety.Acta pharmaceutica Sinica. B · 2022Article
Corrections and comments
- Erratum issuedErratum.2020
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
One of the major design considerations for a drug is its pharmacokinetics in the blood. A drug with a short half-life in the blood is less available at a target organ. Such a limitation dictates treatment with either high doses or more frequent doses, both of which may increase the likelihood of undesirable side effects. To address the need for additional methods to improve the blood half-life of drugs and molecular imaging agents, we developed an "add-on" molecule that contains 3 groups: a truncated Evans blue dye molecule that binds to albumin with a low micromolar affinity and provides a prolonged half-life in the blood; a metal chelate that allows radiolabeling for imaging and radiotherapy; and maleimide for easy conjugation to drug molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.